About Finoso Pharma Private Limited
Data last updated: 10 January 2026
Finoso Pharma Private Limited is a private limited company based in Hyderabad, Telangana, India, a subsidiary of Vivimed Labs Limited. It specialises in pharma contract r and d, a part of the broader pharmaceuticals sector. Incorporated on 18 August 2009, the company has been in operation for over 17 years.
Registered with ROC Hyderabad under CIN U24231AP2009PTC064774.
Capital: an authorised share capital of ₹3.5 Cr and a paid-up capital of ₹3.02 Cr. It is led by directors including Aparna Bidarkar and Kunapareddy Devi Prasad.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: Sp Biotech Park – Phase – I Block – I Turkapally Shameerpet Mandal, Hyderabad, Telangana, India – 500078.
As per the financials filed for FY 2025, the company reported a revenue of ₹17.69 Cr, a decline of 7% compared to the previous year.
The company has a workforce of approximately 15 employees as per the latest available data. It operates as a subsidiary of Vivimed Labs Limited.
The company is associated with 2 brands - Finoso Pharma, Vivimed Labs. As per MCA filings, the company has open charges of ₹4.5 Cr and satisfied charges of ₹2.45 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website finoso.com.
-
Email**************
-
Telephone**************
-
Website**************
-
Social Media**************
-
Registered AddressSp Biotech Park – Phase – I Block – I Turkapally Shameerpet Mandal, Hyderabad, Telangana, India – 500078
-
IndustryPharma, Pharma Contract R&D
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Finoso Pharma Private Limited
Finoso Pharma Private Limited has one previous CIN (Corporate Identification Number): U24231AP2009PTC064774. The current CIN is U24231TG2009PTC064774, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24231TG2009PTC064774 | Current |
| U24231AP2009PTC064774 | Previous |
Associated Brands with Finoso Pharma Private Limited
Finoso Pharma Private Limited operates two associated brands: Finoso Pharma and Vivimed Labs. These brands represent Finoso Pharma Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Offers pharmaceutical formulation research, development, manufacturing, and business services. | finoso.com | |
| Active pharmaceutical ingredients, formulations, and specialty chemicals are manufactured. | vivimedlabs.com |
Competitors & Alternatives of Finoso Pharma Private Limited
Brands and companies operating in the same space as Finoso Pharma Private Limited include Concord Biotech, WuXi AppTec, Almac Group and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Concord Biotech
|
APIs and enzymes are manufactured through fermentation by the CDMO. | Ahmedabad, India, India | 2000 |
WuXi AppTec
|
Provider of CRO and CDMO services | Shanghai, China, China | 2000 |
Almac Group
|
Integrated CDMO services for biopharma R&D and manufacturing are offered. | Craigavon, United Kingdom, United Kingdom | 2001 |
ANI Pharmaceuticals
|
Branded and generic prescription drugs are developed, manufactured, and marketed. | Baudette, United States, United States | 1996 |
Aptar
|
Regulatory support, brand differentiation, and prototyping services are provided. | Crystal Lake, United States, United States | 1992 |
Indoco Remedies
|
APIs manufacturing and formulation services are provided in therapeutic segments. | Mumbai, India, India | 1947 |
CHEPLAPHARM
|
Branded pharmaceutical products are developed, marketed, and distributed globally. | Mesekenhagen, Germany, Germany | 1998 |
Red Nucleus
|
Advisory, scientific, and medical communications provided for pharmaceutical industry. | Yardley, United States, United States | 2014 |
Ipsen
|
Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes | - | 1929 |
Eurofins Scientific
|
Laboratory testing and contract research services are provided globally. | Luxembourg, Luxembourg, Luxembourg | 1987 |
Business Activity of Finoso Pharma Private Limited
Finoso Pharma Private Limited is engaged in the principal business activity of professional, scientific and technical, with detailed activities including scientific research and development.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M5 | Scientific research and development | ********* |
Board of Directors of Finoso Pharma Private Limited
Finoso Pharma Private Limited is currently managed by 3 directors, with 10 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Aparna Bidarkar
Also directs:
Vivimed Labs Limited, Lattice Projex Private Limited
|
Director | 05 Jun 2025 | 1 Years 1 Months | Current |
| Kunapareddy Devi Prasad | Additional Director | 08 Mar 2024 | 2 Years 4 Months | Current |
|
Phaninder Nath Peta Sonti
Also directs:
Vivimed Labs Limited
|
Additional Director | 16 Jul 2025 | 0 Years 11 Months | Current |
Financials of Finoso Pharma Private Limited FY 2025 filings available
Finoso Pharma Private Limited reported revenue of ₹17.69 Cr (down 7% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Charges & Borrowings of Finoso Pharma Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 Dec 2014 | State Bank of India | ₹4.5 Cr | Open |
| 28 Oct 2009 | State Bank of India | ₹2.45 Cr | Satisfied |
Total charge records: 2 View all charges
Employees and EPFO Compliance at Finoso Pharma Private Limited
View historical data on people associated with Finoso Pharma Private Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Finoso Pharma Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Finoso Pharma Private Limited
GSTIN & GST Filing Data of Finoso Pharma Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Finoso Pharma Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Finoso Pharma Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Finoso Pharma Private Limited
MSME Payment Delays by Finoso Pharma Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Finoso Pharma Private Limited
Subsidiaries & Group Companies of Finoso Pharma Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Finoso Pharma Private Limited with ownership details.
MCA Filings & Documents of Finoso Pharma Private Limited
MCA Filings & Documents of Finoso Pharma Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Finoso Pharma Private Limited
Frequently Asked Questions about Finoso Pharma Private Limited
Finoso Pharma Private Limited is an active private limited company in the pharma sector based in Hyderabad, Telangana, India. It was incorporated on 18 August 2009 (17+ years old) and is registered under CIN U24231TG2009PTC064774. The company has 15 employees.
Finoso Pharma Private Limited reported revenue of ₹17.69 Cr for FY 2025 (down 7.00% YoY).
The current directors of Finoso Pharma Private Limited are:
The primary industry of Finoso Pharma Private Limited is pharma. The company specifically operates in pharma contract r and d. The company is currently active in this sector.
Finoso Pharma Private Limited can be reached at the registered office: Sp Biotech Park – Phase – I Block – I Turkapally Shameerpet Mandal, Hyderabad, Telangana, India – 500078, or through the website finoso.com.
The authorised capital is ₹3.5 Cr, and the paid-up capital is ₹3.02 Cr.